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Background: Inhalation of endotoxin (LPS) induces a predominantly neutrophilic airway inflammation and has
been used as model to test the anti-inflammatory activity of novel drugs. In the past, a dose exceeding 15–50 μg
was generally needed to induce a sufficient inflammatory response. For human studies, regulatory authorities in
some countries now request the use of GMP-grade LPS, which is of limited availability. It was therefore the aim of
this study to test the effect and reproducibility of a low-dose LPS challenge (20,000 E.U.; 2 μg) using a flow- and
volume-controlled inhalation technique to increase LPS deposition.
Methods: Two to four weeks after a baseline sputum induction, 12 non-smoking healthy volunteers inhaled LPS on
three occasions, separated by at least 4 weeks. To modulate the inflammatory effect of LPS, a 5-day PDE4 inhibitor
(Roflumilast) treatment preceded the last challenge. Six hours after each LPS inhalation, sputum induction was
performed.
Results: The low-dose LPS inhalation was well tolerated and increased the mean percentage of sputum neutrophils
from 25% to 72%. After the second LPS challenge, 62% neutrophils and an increased percentage of monocytes
were observed. The LPS induced influx of neutrophils and the cumulative inflammatory response compared with
baseline were reproducible. Treatment with Roflumilast for 5 days did not have a significant effect on sputum
composition.
Conclusion: The controlled inhalation of 2 μg GMP-grade LPS is sufficient to induce a significant neutrophilic
airway inflammation in healthy volunteers. Repeated low-dose LPS challenges potentially result in a small shift of
the neutrophil/monocyte ratio; however, the cumulative response is reproducible, enabling the use of this model
for “proof-of-concept” studies for anti-inflammatory compounds during early drug development.
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Endotoxin (lipopolysaccharide, LPS) is a potent pro-
inflammatory constituent of the outer membrane of
Gram-negative bacteria. It occurs in a number of envi-
ronments [1] and is a constituent of tobacco smoke [2]
and particulate matter in indoor and outdoor aerosols
[3]. Provocation of the lung with LPS induces a predom-
inantly neutrophilic type of inflammation and has been
used to study inflammatory processes. LPS challenges of
the lung via inhalation or segmental application have
also been used as models to test the anti-inflammatory
activity of investigational new drugs [4]. The segmental
application of LPS is very well controlled, as one lung
segment serves as baseline, while two other segments
are challenged with saline or LPS [4,5]. Only very little
LPS is needed (4 ng/kg body weight) to elicit a robust
influx of neutrophils or monocytes. However, the model
requires repeated bronchoscopies, which limit its wide-
spread use.
An alternative less invasive approach is LPS delivery to
the lung by inhalation and the assessment of inflamma-
tion by analysis of induced sputum or exhaled nitric
oxide. This has been done in healthy volunteers [6-10],
in subjects with bronchial asthma [11-13], and recently
in healthy smokers [14]. LPS inhalation has also been
used to test the effect of salmeterol [15,16] and to com-
pare the anti-inflammatory potential of a PDE4 inhibitor
with a corticosteroid [17].
In these studies, however, rather large doses of LPS
(15–50 μg) were required to induce a sufficient inflamma-
tory response [14,17,18]. In Germany and other countries
authorities now require GMP-grade LPS (manufactured
under Good Manufacturing Practice standards) to be used
for administration to humans. Clinical Center Reference
Endotoxin provided by the NIH Clinical Center fulfills
these criteria; however, it is of limited availability. There-
fore, future clinical trials will need to manage LPS provo-
cations with lower doses.
The available publications about low-dose LPS inha-
lation studies (< 5 μg) report either no cellular increases
[6] or only minor effects [9]. In one study that showed
a clear increase in sputum neutrophils after inhalation
of 20,000 Endotoxin Units (i.e. 2 μg) [8], the baseline
sputum induction was performed just prior to the LPS
challenge, which could have enhanced the neutrophil
response [19].
The only way to augment the effect of a low dose of
inhaled LPS is to increase the amount of LPS that
reaches the lung. It has been shown that the deposition
of inhaled therapeutics can be improved by controlling
the inhaled volume and the flow rate. This also reduces
inter-subject variability of total particle deposition com-
pared with uncontrolled inhalation [20]. We adopted
this approach using a nebulizer with a very small deadvolume (< 0.1 mL) and a computer controlled mass flow
controller. After each inhalation of the LPS containing
aerosol bolus, an additional air bolus was inhaled and
the deposition was further enhanced by including a short
end-inspiratory breath hold.
In this study we first thought to investigate whether
the use of an improved inhalation procedure with a low
dose of LPS elicits a sufficiently large inflammatory re-
sponse, to be used in proof-of-concept studies. Secondly,
we wanted to assess whether this inflammatory response
is repeatable. Therefore we carried out a second LPS
challenge after a four-week washout period. Finally, we
tested whether a 5-day treatment with the recently ap-
proved PDE4 inhibitor Roflumilast (DaxasW) is able to
modify the inflammatory response to LPS. Initially, we
had planned to use a steroid for anti-inflammatory treat-
ment (clinicaltrials.gov: NCT01400568), which is stand-
ard in the ozone challenge model [21] that also serves to
induce a temporary neutrophilic airway inflammation.
However, with the availability of the PDE4 inhibitor
Roflumilast we decided to change to this approved COPD
treatment, to include a more relevant positive control in
the low-dose LPS challenge model that is planned to be
used mainly in proof-of-concept studies with novel anti-
inflammatory treatments developed in the field of COPD.
Methods
Study population
Twelve healthy, non-smoking volunteers (non-smokers
for at least 5 years, history of < 1 pack year), 18–55 years
old, were included in the study. The ability to produce
an adequate sputum sample (≥ 1 × 106 total cells, ≤ 50%
neutrophils, ≤ 20% squamous epithelial cells) was tested
at the baseline visit prior to inclusion. All subjects
showed a normal airway response to methacholine (pro-
vocative concentration leading to a 20% fall in FEV1
(PC20FEV1) > 8 mg/mL). The study was approved by the
Ethics Committee of the Hannover Medical School, and
written informed consent was obtained from all subjects.
Study design
This study was conducted as a non-randomized, 3-part
study (Figure 1), and we included the results of a separ-
ate follow-up study to obtain data of another baseline
sputum. The screening visit included documentation of
the medical history and concomitant medication, an ex-
tensive medical examination including 12-lead electro-
cardiogram, lung function and allergy testing, a drug
screening, and a pregnancy test for female subjects.
Bronchial hyperresponsiveness was excluded by a me-
thacholine challenge test. At visit 2, baseline sputum was
induced and served as reference sputum for all further
challenges. Challenge visits 3, 5, and 8 comprised LPS
inhalation and, 6 h later, the induction of sputum
Figure 1 Study design. LPS: inhalation of 2 μg (20,000 E.U.) nebulized Lipopolysaccharide. Treat: Oral administration (500 μg/day) of the PDE-4
inhibitor Roflumilast. FACS: Flow cytometry of sputum cells was performed. In a separate study performed >56 days after the end of the LPS
challenge trial, 11 subjects underwent a follow-up sputum induction. (Visits 4, 6, and 9 refer to phone calls done 24 h after the
respective challenges).
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6 h after LPS challenge (not at visit 3). Exhaled breath-
(X-halo thermometer, Delmedica) and body- (DINAMAP
Pro200) temperatures were recorded prior to, 3 h, and 6 h
after the LPS challenges. Lung function (FEV1) was mea-
sured by spirometry before, immediately after LPS inhal-
ation, and prior to sputum induction. Pulmonary function
was also monitored hourly for 6 h, as well as 9, 11, 13, and
24 h after the challenge by a portable asthma monitor
(VIASYS Healthcare). A physical examination and a
pregnancy test for female subjects preceded each LPS
challenge, and any adverse events were recorded. Oral
medication (Roflumilast, 500 μg/d) was administered
for 5 days every morning including the LPS challenge
day (visit 8).
All subjects except one agreed to participate in the
follow-up study which included a sputum production
with separate written informed consent obtained from
all subjects. This visit was performed at least 8 weeks
after the last LPS challenge and the data was used to fur-
ther interpret the results of this study.Figure 2 Procedures performed on challenge days LPS 1, LPS 2 and L
breath temperature, BT = body temperature, LPS = low dose lipopolysaccha
(LPS1). Lung function was also monitored by a portable AM1 detector hou
function results and the subject’s symptoms at 24 h were assessed by phoLPS inhalation challenge
LPS (Clinical Center Reference Endotoxin CCRE; Na-
tional Institutes of Health Clinical Center, Bethesda, USA)
was dissolved in saline to a final concentration of 2 μg/mL
(20,000 E.U./mL). The LPS solution was nebulized using
an Aeroneb solo nebulizer (Inspiration Medical, Bochum,
Germany) with a very small residual volume (< 0.1 mL).
Each inhalation cycle lasted 10 seconds, using a mass-flow
control unit to adjust the airflow to 150 mL/s: During the
first 5 seconds, 750 mL air with nebulized LPS was in-
haled, followed by 300 mL air-only over 2 seconds. An
end-inspiratory breath-hold of 3 seconds completed each
cycle. All subjects inhaled a total amount of 2 μg (20,000
E.U.) LPS at each challenge visit. The whole procedure
lasted approximately 15 min.
Sputum analysis
Subjects inhaled increasing concentrations of nebulized
(OMRON NE-U17, Mannheim, Germany) hypertonic
saline (3%, 4%, 5%) for 10 minutes each. Sputum “plugs”
were selected from saliva and controlled by microscopePS Tx (Figure 1). FEV1 = lung function measurement, EBT = exhaled
ride challenge (20,000 E.U.), 1 blood samples were not taken at visit 3
rly for 6 h, as well as 9, 11, 13, and 24 h after LPS challenge. Lung
ne call.
Table 1 Median (IQR) temperature (°C)
Body ** Breath*
LPS 1
pre 36.2 (0.8) 33.8 (1.1)
3 h post 36.2 (0.9) 33.6 (0.5)
6 h post 36.7 (0.3)## 33.9 (0.5)
LPS 2
pre 36.4 (0.5) 33.7 (0.4)
3 h post 36.2 (0.6) 33.7 (0.3)
6 h post 36.6 (0.6)§ 34.0 (0.5)
LPS Tx
pre 36.3 (0.6) 33.8 (0.5)
3 h post 36.3 (0.5) 34.2 (0.7)
6 h post 36.7 (0.3)## 33.9 (0.6)
** p < 0.01, *p < 0.05 for repeated measures ANOVA with visit (LPS1, 2, Tx) as a
factor. Newman-Keuls post-hoc test: ## p < 0.01, § p = 0.08 compared
with “pre”-challenge.
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pooled plugs were incubated with 4 volumes of 0.1% di-
thiothreitol (DTT, Sputolysin; Calbiochem, La Jolla, USA)
for 15 min. After adding 4 volumes of Dulbecco’s phos-
phate-buffered saline (DPBS; Lonza, Verviers, Belgium),
the homogenized sputum sample was filtered (70 μm, BD,
Heidelberg, Germany) and centrifuged (790 × g, 10 min).
Total cell number and cell viability were determined with
a Neubauer hemacytometer (trypan blue staining). Spu-
tum supernatant was frozen at −80°C until analysis. For
flow cytometry the cell pellet was resuspended in FACS-
buffer (PBS, 5% fetal calf serum, 0.5 mM EDTA),
centrifuged (790 × g, 5 min), and resuspended in FACS-
buffer. Cytospots were prepared (Cytospin; Shandon,
Pittsburgh, USA) and stained with Diff-Quik (Medion
Diagnostics, Düdingen, Switzerland). Differential cell
counts were performed by two experienced, independent
observers from 400 non-squamous cells, and the results
were averaged. The presented data on monocytes and
small macrophages was derived from the cytospin analysis.
Cytokine concentrations in sputum supernatants were
measured by ELISA, using commercial kits for both
the detection of interleukin-8 (IL-8, R&D systems,
Minneapolis, USA) and myeloperoxidase (MPO, Bio
Vendor, Brno, Czech Republic). Samples were diluted
1:100 to assure cytokine concentrations within the
range of the respective standard curves (limit of de-
tection: 31.25 pg/mL for both IL-8 and MPO).
Flow cytometry of sputum cells
An aliquot of the sputum sample was used for flow-
cytometric analysis (Cytomics FC500; Beckman Coulter,
Krefeld, Germany). Staining included fluorochrome-
labeled antibodies from BD Biosciences (CD4 (FITC)/8
(PE), CD86 (PE-Cy7), HLA-DR (PE)) and Beckman Coul-
ter (CD14 (APC)) and the respective non-specific isotype
control antibodies from the same sources. To quantify
sputum cell subpopulations, leukocytes were differentiated
from cellular debris and squamous epithelial cells and fur-
ther differentiated into leukocyte subpopulations by gating
strategies based on light scatter properties (forward scat-
ter: FSc, sideward scatter: SSc) and specific surface mar-
kers. To assess the expression of selected cell surface
molecules such as HLA-DR and CD86 on gated macro-
phage populations, the mean fluorescence intensity (MFI)
was measured. Specific isotype controls were subtracted
from the respective MFI values. Changes (MFI difference)
in the expression of these cell surface molecules were
evaluated by comparing baseline and post challenge spu-
tum cells.
Statistical analysis
Data are displayed as arithmetic and geometric mean
and standard error of the mean (SEM) or median andinterquartile ranges (IQR). Repeated measures analysis
of variance (ANOVA) was used to compare variables be-
tween visits. Data were log-transformed if not normally
distributed. The Newman-Keuls-test was used for post-
hoc analysis. Intra-class correlation coefficients (ICC)
were derived from one-way ANOVA tables as the ratio
of variance among subjects to total variance based on
the repeated measurements [22]: (BMS-WMS/2)/((BMS-
WMS/2) +WMS); BMS = between group mean square,
WMS = within group mean square. A p-value < 0.05 was
considered significant. For the statistical analysis we
used Statistica (Statsoft, Hamburg, Germany).
Results
Demographics
Eighteen subjects were screened to enroll 12 subjects for
the study. Three subjects were not included because of
abnormal lung function or smoking history, 1 due to air-
way hyperresponsiveness, and 1 due to an inadequate
sputum sample. One subject was screened in reserve,
but inclusion was not required. Twelve subjects (3 fe-
male / 9 male) completed the study. The mean (SD) age
was 38 ± 11 years and the mean FEV1 was 104.2 ± 7.3%
predicted.
Systemic effects of LPS
Inhalation of LPS was well tolerated with no adverse
events being observed. Only a small effect on lung
function was detected 1 h after LPS challenge. FEV1
decreased to a median (IQR) of 95.9 (9.2)% of pre-
challenge values (p < 0.01). All subsequent measurements
up to 24 h post LPS were not significantly different from
pre-challenge values. Body temperature was slightly in-
creased 6 h after LPS challenge (Table 1). The increase in
exhaled breath temperature was even smaller, but statisti-
cally significant (ANOVA, p = 0.011, Table 1).
Compared with the screening visit we observed an
increase in the median (IQR) total number of blood
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centage of blood neutrophils (54.1 (9.4) vs. 74.1 (9.4)%)
after LPS challenge (LPS 2). Correspondingly, the per-
centages of monocytes (10.4 (2.8) vs. 7.3 (1.7)%) and
lymphocytes (31.9 (9.8) vs. 18.7 (7.0)%) decreased. These
changes were statistically significant (ANOVA p < 0.001,
each). No differences were observed in the percentage
and total number of blood neutrophils and blood mono-
cytes, when baseline and pre-challenge values were com-
pared (baseline vs. LPS 2 vs. LPS Tx, Figure 2).
Airway inflammation induced by low dose LPS challenge
All subjects produced adequate sputum samples through-
out the study. Sputum production after LPS challenges
was generally easier for subjects, as compared with the
baseline sputum induction. The lower squamous cell con-
tamination in sputum samples from these visits also indi-
cates that sputum plugs were easier to select than in
samples of the baseline visit.
Inhalation of 20,000 E.U. GMP-grade LPS induced a
massive influx of neutrophils into the airways (Figure 3,
Table 2). Both the increase in the percentage and in the
number per mL sputum compared with baseline was sta-
tistically significant. However, the neutrophilic response to
the second LPS challenge was lower compared with the
first challenge. LPS also induced an influx of monocytes
and small macrophages. With respect to their percentage,
this effect was significant only after the second LPS
challenge. The cumulative inflammatory response (sum
of neutrophils, monocytes, and small macrophages; see
Additional file 1: Figure S1) showed a smaller difference
in percentages after the two repeated LPS challenges.
No effects were observed for eosinophils, lymphocytes,
and non-squamous epithelial cells. The total sputum cellFigure 3 Sputum neutrophils (left) and the sum of sputum monocyte
percent sputum leukocytes are displayed. BL: baseline, LPS 1: first LPS chall
third LPS challenge at least 4 weeks after LPS 2 and after 5 days of treatme
Table 2. ** p < 0.01, *** p < 0.001 compared with baseline; # p < 0.05 compcount increased after both LPS challenges, but was lower
after the second compared with the first LPS challenge.
Hence, the total neutrophil count showed a significant dif-
ference between the LPS challenges, while the numbers of
monocytes and small macrophages were not different.
After LPS challenges, a mild increase in the sputum
concentration of total protein was observed. Median
(IQR) concentration at baseline, after LPS 1, LPS 2, and
LPS Tx were 2.40 (0.98), 3.05 (1.26), 2.70 (0.74), and
2.78 (1.20) mg/mL, respectively (ANOVA, post-hoc test
compared with baseline p < 0.05 each). Figure 4 shows
the significant increases in the sputum concentration of
IL-8 (ANOVA: p < 0.001) and MPO (p < 0.0005) and also
illustrates that no differences between LPS 1 and LPS 2
could be observed for both these markers.
Effect of low dose LPS challenge after treatment with
Roflumilast
Prior to the third LPS challenge, all subjects were treated
for 5 days with 500 μg Roflumilast/day (DaxasW) to test
the potential modulation of the LPS response by an anti-
inflammatory treatment. Only small changes in sputum
composition were observed compared with the LPS
challenges without treatment (Table 2). The percentage
of neutrophils was significantly lower compared with the
first, but not compared with the second LPS challenge.
The lowest total cell count after LPS challenges was
found after treatment with Roflumilast. Again, this de-
crease was statistically significant compared with the
first LPS challenge, but not with the second. Comparable
results were obtained for the numbers of neutrophils
and macrophages. The inflammatory mediators IL-8
and MPO were not affected by the treatment with
Roflumilast.s and small macrophages (right). Individual data and mean values of
enge, LPS 2: second LPS challenge at least 4 weeks after LPS 1, LPS Tx:
nt with Roflumilast (500 μg /day). For statistical details please refer to
ared with LPS 1.
Table 2 Sputum composition (percentage of sputum leukocytes and cell count)
ANOVA
Baseline LPS 1 LPS 2 LPS Tx p
Macrophages (%)§ 68.7 ± 5.3 19.1 ± 2.9*** 25.9 ± 3.5*** 27 ± 4.5*** <0.001
Neutrophils (%)§ 25.2 ± 5.0 72.3 ± 3.4*** 61.5 ± 3.5*** 61.8 ± 4.6*** # <0.001
Eosinophils (%)§ 0.0 ± 0.0 0.1 ± 0.0 0.2 ± 0.1 0.1 ± 0.1 n.s.
Lymphocytes (%)§ 0.7 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.4 ± 0.1 n.s.
Monocytes/sm. MФ (%)§ 5.3 ± 0.9 7.9 ± 1.4 11.9 ± 1.5*** # 10.7 ± 0.9** 0.001
Cummulative Response (%)§ 30.5 ± 5.4 80.3 ± 3.0*** 73.3 ± 3.5*** 72.5 ± 4.5*** <0.001
Sq. cells (% TCC)& 7.7 (1.4) 2.9 (1.2)*** 2.5 (1.4)*** 2.8 ± 1.3*** <0.001
Total cell count (106/mL)& 2.40 (1.2) 10.46 (1.2)*** 5.08 (1.2)** ## 3.7 (1.2)*### <0.001
Macrophages (106/mL)& 1.43 (1.2) 1.73 (1.2) 1.11 (1.3) 0.80 (1.2)* # 0.02
Neutrophils (106/mL)& 0.39 (1.5) 7.29 (1.3)*** 2.91 (1.3)***## 2.10 (1.2)***### <0.001
Non-Sq. epithelia cells (106/mL)& 0.15 (1.4) 0.12 (1.5) 0.14 (1.5) 0.09 (1.4) n.s.
Monocytes/sm. MФ (106/mL)& 0.10 (1.3) 0.66 (1.4)*** 0.52 (1.3)*** 0.36 (1.2)*** <0.001
Cummulative Response (106/mL)& 0.53 (1.4) 8.13 (1.2)*** 3.47 (1.2)***## 2.51 (1.2)***### <0.001
§ mean and standard error of the mean (SEM) of percent sputum leukocytes, & geometric mean and geometric standard error (SEM as a factor), TCC: total cell
count; Sq: Squamous; sm. MФ: small macrophages; ANOVA: repeated measures ANOVA, Newman-Keuls post-hoc test: * p < 0.05, ** p < 0.01, *** p < 0.001
compared with baseline; # p < 0.05, ## p < 0.01, ### p < 0.001 compared with LPS 1. Cumulative response = Sum of neutrophils, monocytes and
small macrophages.
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tum macrophages showed an increase in the MFI of these
markers after treatment with Roflumilast (Additional file 1:
Figures S2 and Additional file 1: Figures S3).
Reproducibility of the LPS response
In this study, the LPS challenge was performed twice to
test the repeatability of the response. Compared with
baseline, both provocations resulted in a significant in-
crease in the percentage of neutrophils, but with a lower
influx of neutrophils in the second challenge, as can beFigure 4 Concentrations of IL-8 and MPO in sputum supernatants. Ind
BL: baseline, LPS 1: first LPS challenge, LPS: second LPS challenge at least 4
LPS 2 and after 5 days of treatment with roflumilast (500 μg /day). For stati
with baseline.seen by a value for the mean difference below zero in
the Bland-Altman plot (Figure 5A) and a deviation from
the line of identity (Figure 5B). Despite this, there was a
significant correlation between the two repeated chal-
lenges for the increase from baseline (r = 0.79). The intra-
class correlation coefficient (ICC) was 0.63.
The lower proportion of neutrophils in the second
challenge could partly be due to a higher proportion of
monocytes/small macrophages. As LPS is well known
to cause both a neutrophilic and a monocytic influx,
we also analysed the cumulative response to LPS byividual data and mean values of log transformed values are displayed.
weeks after LPS 1, LPS Tx: third LPS challenge at least 4 weeks after
stical details please refer to Table 2. *** p < 0.001 compared
Figure 5 Reproducibility of the low dose LPS induced inflammatory response (LPS 1 vs. LPS 2). Top row (A, B): Change in the percentage
of sputum neutrophils compared with baseline. Bottom row (C, D): Change in the percentage of the sum of neutrophils, monocytes and small
macrophages compared with baseline. On the left (A, C) Bland-Altman plots with lines indicating the mean and 2*SD of the differences and on
the right (B, D) the respective correlations with the line of identity.
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macrophages (Figure 5C and D). Both the correlation
coefficient and the ICC showed higher values for the
cumulative response (r = 0.87, ICC = 0.81). We also ana-
lysed the reproducibility between LPS 2 and LPS Tx for
neutrophils and the cumulative response (neutrophils:
r = 0.93, ICC = 0.87, cumulative resp.: r = 0.94, ICC = 0.87).
While we observed an increase in sputum total cell
count and in the cell counts of individual cell types after
both LPS 1 and LPS 2, neither the cell counts nor the re-
spective changes from baseline showed a significant cor-
relation between the two LPS challenges (LPS 1, LPS 2).
Sample size calculation for future studies
Based on the data of this study, we calculated the num-
ber of subjects, which would be required for a proof-
of-concept study. To detect a 50% reduction of the LPS
induced neutrophil level, 15 healthy subjects would need
to be included. For the cumulative inflammatory re-
sponse as an endpoint, the number would be reduced to
13. For a more detailed listing, refer to Additional file 1:
Table S1.Comparison between methods
No significant relationship between any of the blood
markers and the inflammation detected by induced
sputum was observed. There was also no relationship
between breath or body temperature and sputum
markers.
The sputum slides were independently evaluated by a
clinical cytologist. The differential cell counts between
his results and the mean of the two independent eval-
uators were highly correlated (e.g. neutrophils: r = 0.89).
No differences between visits with respect to scores for
other morphological features (macrophages: degree of
vacuolisation; epithelia cells: number and size of nuclei)
were observed.
Comparison between baseline and follow-up
(unchallenged conditions)
Compared with the baseline visit of this study we ob-
served a small but significant increase in the propor-
tion of neutrophils (median (IQR): 19.4 (33.0)% vs. 29.6
(31.2)%, p = 0.02) in a follow-up visit, which was per-
formed at least 57 days (max. 156 days) after the end of
Janssen et al. BMC Pulmonary Medicine 2013, 13:19 Page 8 of 11
http://www.biomedcentral.com/1471-2466/13/19the last LPS challenge. This was accompanied by a slight
decline in the proportion of monocytes and small mac-
rophages (4.2 (2.4)% vs. 2.7 (2.4)%, n.s.). Neither the per-
centage of the sum of neutrophils, monocytes and small
macrophages, nor any cell count per sputum weight
showed a significant difference between these two visits.
The increased levels of HLA-DR and CD86 expression
on sputum macrophages observed after treatment with
Roflumilast had returned to the levels observed after
LPS treatment only (LPS 2).
Discussion
Using a flow- and volume-controlled inhalation, we were
able to improve the deposition of LPS in the lung and to
elicit a pronounced and significant inflammatory re-
sponse in healthy volunteers using a low dose of 20,000
E.U. (2 μg) LPS. When repeating the procedure after a 4
week washout period, the overall inflammatory response
was shown to be reproducible; however, we did observe
a small decline in the neutrophil/monocyte ratio after
the second LPS challenge. Treatment with the PDE4-
inhibitor Roflumilast for 5 days changed the expression
of HLA-DR and CD86 on sputum macrophages, but did
not result in a significant attenuation of the inflamma-
tory cell influx. Our data suggests that the low-dose
challenge required for the use of GMP-grade endotoxin
is suitable for “proof-of-concept” studies of novel com-
pounds targeting neutrophilic and monocytic airway
inflammation.
Regulatory authorities increasingly control the origin
and production of substances used for airway provoca-
tion. In Germany only GMP-grade LPS, such as CCRE
produced by the NIH Clinical Center, is allowed to be
used for these purposes. This material is also increas-
ingly being used for studies in the USA [9,12]. As this
material is of limited availability, an improved deposition
and a nebulizer with a small residual volume were es-
sential for our study. Flow controlled inhalation of ne-
bulized aerosols can greatly improve deposition [20].
Although the AKITAW inhalation system is a commer-
cially available device with integrated flow control, we
could not use this system in this study, as the death vol-
ume of its jet nebulizer is too large. Therefore we used
the Aeroneb solo nebulizer (Inspiration Medical), which
creates the aerosol using a high-frequency vibrating
membrane with 1000 precision-cut openings, working
basically like a micro-pump system. Here, the residual
volume of LPS was generally below 100 μL. This ne-
bulizer was combined with a mass-flow control unit that
limited the inhalation flow and applied air only during
the end of each inspiration. The controlled inhalation
most likely increased the lung deposition of LPS by
avoiding the unwanted deposition in the mouth and
pharynx.Inhalations of low LPS doses were safe and well to-
lerated. Only a small decrease in lung function was
detected, but the affected subjects did not report any
symptoms. The extent of systemic effects was in the
expected range, with an increase in body temperature of
less than 1°C. The blood total leukocyte and neutrophil
count increased, but this is known to occur even after
exposure to a low dose of LPS, that does not elicit a
detectable change in the composition of airway leuko-
cytes [6].
The main focus was the analysis of induced sputum.
Compared with a previous study that used the same
dose of LPS [9], the neutrophilic response was more
pronounced. The 6 h time point after LPS inhalation has
been used frequently to assess the inflammatory effect;
however, there are conflicting results with respect to the
maximal effect. In a study by Doyen et al., the peak neu-
trophil cell count was detected 24 h after the challenge
[18], which is in line with data from endobronchial LPS
challenges. A more pronounced effect at 6 h was re-
cently shown by Aul and coworkers [14], but this was in
healthy smokers.
Using induced sputum to assess the inflammatory re-
sponse to LPS, we assessed cytospin slides after the first
LPS challenge. While the neutrophil influx was clearly
detectable, we also saw increased numbers of smaller
macrophages and monocytes. Therefore, we included
flow cytometry into our analysis of sputum composition
after the second LPS challenge and measured the pro-
portion of monocytes using CD14 staining. Comparison
of the flow cytometry data with the mean cytospot cell
count of two independent observers showed a good cor-
relation for macrophages and neutrophils. We also
found a fairly good relationship between CD14-positive
cells and the sum of monocytes and small macrophages,
supporting our approach to count these cells together
(Additional file 1: Figure S4). For a more detailed flow
cytometric analysis of induced sputum please refer to
Lay et al. [23].
Looking at the data derived from the cytospot analysis,
we observed only a small increase in the proportions of
monocytes and small macrophages after the first, but a
significant increase after the second LPS challenge. This
effect could partly be responsible for the lower neutro-
phil proportion detected after the repeated LPS chal-
lenge. However, changes in cell proportions are difficult
to interpret. We would, therefore, recommend using the
cumulative response to LPS consisting of neutrophils,
monocytes, and small macrophages as an additional out-
come in future LPS trials. The reproducibility of this
cumulative response compared with baseline was also
better than for sputum neutrophils alone.
The development of tolerance could also be a reason,
why the response to the second LPS challenge was
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ever, it has not been seen this clearly in a LPS inhalation
trial before. Loh et al. suggested that tolerance would be
visible only at low doses of LPS [27], but there are no
studies available looking at repeated low-dose LPS chal-
lenges. In a recently published paper by Aul et al. [14], a
dose comparable to the one used by Loh et al. was in-
haled and no tolerance was detected, But Aul and col-
leagues challenged healthy active smokers, who are
constantly exposed to LPS from cigarette smoke at rele-
vant levels [2], and might therefore show a more homo-
geneous response. While this would be in favour for
including only active smokers into LPS challenge proof-
of-concept studies, the level of acute smoking is gener-
ally not easy to control and could bias drug effects in
numerous ways. Based on our results, it appears to be
advisable to include a screening LPS challenge, when
planning proof-of-concept studies with healthy subjects.
This was not actually tested in our trial; however, we did
not see a further decline in neutrophils in the third LPS
challenge, therefore, a bias due to a tolerance effect ap-
pears to be limited to the second LPS challenge in
healthy subjects. In addition, the reproducibility between
the second LPS challenge (LPS 2) and the LPS challenge
after treatment (LPS Tx) was clearly better than between
LPS 1 and LPS 2.
Interestingly, we did not see an attenuated response in
the second challenge with respect to IL-8 and MPO
levels in the sputum supernatant, indicating that either
the sputum supernatant analysis is less sensitive or that
other mechanisms than simply chemo-attraction are in-
volved in determining the cellular response to LPS.
Comparison of sputum of 11 subjects collected on
average more than 3 months (median 111, minimum 56,
maximum, 157 days) after the last LPS inhalation re-
vealed a higher mean neutrophil count as compared to
the baseline visit of this study (median between baseline
sputum inductions: 203 days (minimum: 191, maximum:
245). Despite this, neutrophil percentages were highly
correlated (r = 0.86). It could be speculated that the rea-
son for the increase is season-related, as baseline sputum
of this study was obtained during late summer 2011
(August/September) and the repeated measurements were
taken in early and colder springtime 2012 (March/April).
In this study, we investigated the effect of a 5 day
treatment with Roflumilast, a duration of treatment dur-
ing which a steady-state level in serum can be achieved
[28,29]. In primates treated with a comparable dose
(7 μg/kg body weight per day for 5 days), a small decline
in BAL neutrophil numbers and percentage was ob-
served [30]. In our study, the effect of Roflumilast treat-
ment on sputum neutrophil percentage was small and
only significant when the results after treatment were
compared with the first LPS challenge. This is in linewith data of COPD patients and of asthma patients after
allergen challenge, obtained in two studies in which the
treatment period exceeded 14 days, but did not find an
effect on the percentage of sputum neutrophils [31,32].
Furthermore, Roflumilast was not able to change the
relative cellular composition of BAL in healthy subjects
after 4 weeks of treatment and segmental LPS challenge,
while it reduced absolute neutrophil numbers [4].
With respect to the total sputum cell count and the
neutrophil cell count, we observed the lowest values
after Roflumilast treatment, but this decline did not
reach statistical significance compared with the second
LPS challenge. Based on the data in primates, we hy-
pothesized that a 5 day treatment duration, would prove
efficacious on neutrophil cell numbers. Nevertheless, the
small effect on cell numbers seen in our study is com-
patible with the effects seen in the above mentioned
studies [4,31,32]. The strongest effect on sputum neutro-
phil cell numbers was observed after 4 weeks of treatment.
Notably, even a 4 or 2 week treatment with Roflumilast
did not have profound effects on sputum inflammatory
mediators, which is in line with our results. The de-
crease of IL-8 in COPD was borderline significant,
and Roflumilast did not change sputum IL-8 and MPO
after allergen challenge in asthmatic patients [31,32]. Fi-
nally, it could be speculated that in sputum, which has a
higher baseline neutrophil count than BAL (approximately
20–30% compared to < 3%), there is less room for im-
provement of a given treatment upon endotoxin challenge
and therefore effects on neutrophils are more difficult to
demonstrate.
Interestingly, we found an increase in the expression
of HLA-DR and CD86 on sputum macrophages. This in-
crease was unexpected. While we can only speculate on
the Roflumilast driven mechanism, we interpret this con-
sistent finding in all subjects as an indicator for treatment
compliance. Our study design was not randomized, as a
clear sequence of experiments was required, in order to
answer our questions. A randomized sequence would have
been likely to show a larger treatment effect, but this
would have been biased by an unnoticed tolerance effect.
Conclusion
In summary, our study has shown that a low-dose
of LPS, delivered by an efficient inhalation procedure,
elicits a significant inflammatory response within the air-
ways. We were also able to demonstrate that the im-
munological response to a low dose of LPS is complex,
inducing not only the influx of neutrophils and mono-
cytes into the airways, but potentially also involving
small carryover effects and signs for the development of
LPS tolerance. To utilize the advantages of an LPS
model in human subjects for proof-of-concept studies,
it is therefore important to assess the inflammatory
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with the non-invasive method of sputum induction. We
recommend including the cumulative cellular influx, the
sum of neutrophils and monocytes/small macrophages,
as an outcome variable. In addition, when performing
studies with healthy subjects, a screening LPS challenge
should be included to achieve a more homogeneous in-
flammatory response during the actual study period,
which is then less likely to be affected by a potential tol-
erance bias.
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